NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

I-Mab Expands U.S. Footprint with New R&D Site in San Diego

by Emma Jones
October 23, 2021
A A

– I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growing San Diego biotech hub

– The new site will complement I-Mab’s Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&D Center for global drug development

SHANGHAI, China and GAITHERSBURG, MD – October 22, 2021 – I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will establish a new site focusing on Translational Medicine and Formulation Research in San Diego. The state-of-the-art, integrated laboratory and office space will strengthen the Company’s worldwide development capabilities, further reinforcing I-Mab’s ability to conduct global clinical studies across China and the U.S.

“Our vision for our new San Diego location is to establish a world-class research and operational site as part of I-Mab US R&D Center that will support our mission to deliver first and best in class medicines to patients worldwide,” said Dr. Jingwu Zang, Founder, Chairman and Director of I-Mab. “We’re very excited about our new research site in San Diego, which will complement our research and development facilities around the world to advance our innovative pipeline globally.”

“As a dynamic and growing U.S. biotech hub, San Diego was a great choice due to its large pool of biopharma talent and proximity to many of the world’s leading research institutions,” said Neil Warma, General Manager of I-Mab US. “We have been able to attract world-class individuals across several key functions to our new San Diego location and are completing final construction of the site, with move-in planned toward the end of the year. It’s a very exciting time for I-Mab as we expand our capabilities strategically to conduct clinical development on a global scale to advance novel therapies for patients,” Mr. Warma added.

Founded in 2016, I-Mab is committed to bringing innovative treatments for cancer to patients globally, drawing on the scientific strengths of the Company in immuno-oncology and its robust pipeline of 20 innovative assets in development. The San Diego site will serve as one of strategic sites for I-Mab’s global drug development efforts, and will include a comprehensive biomarker platform that will support current and future clinical trials. The new research site will be an integral part of I-Mab’s US R&D Center together with the Global Clinical Development site established in 2018 in Gaithersburg, Maryland, which is focused on global clinical development and regulatory affairs.

The Company is preparing for rapid growth over the next two years through significant investments in the United States to support development of its innovative pipeline.  The facility will serve as a specialized research site for worldwide development efforts alongside the hiring of key talent in immuno-oncology, translational medicine, Chemistry, Manufacturing, and Controls (CMC).

Tags: < Invest | M&A
ShareTweetShareSend

Related Industries

Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023
Healthcare

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023
Healthcare

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023
Healthcare

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023
Healthcare

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023
Healthcare

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

May 10, 2023

IonicBlue® receives up to CAD $100 million investment from Canada Infrastructure Bank toward decarbonization projects

May 24, 2023

...

Rockwell Automation Named Leader in Gartner® 2023 Magic Quadrant™ for Manufacturing Execution Systems

May 4, 2023

...

Kimberly-Clark Professional Announces Greenovation Awards For Sustainability Leadership And Waste Reduction

May 6, 2023

...

PPG appoints Christine Camsuzou vice president, procurement and chief procurement officer

May 3, 2023

...

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

May 10, 2023

...

Morgan Stanley Capital Partners Acquires RowCal

May 2, 2023

...

ABB opens Robert M. Thomas Innovation Center in Memphis

May 19, 2023

...

Toshiba Named a Major Player in the IDC MarketScape “Worldwide Retail Commerce Platform Software Providers 2023 Vendor Assessment”

May 17, 2023

...

Hyundai Motor Premieres Commercialized Model of Its XCIENT Fuel Cell Tractor and Vision for Hydrogen Mobility in US

May 3, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.